UDCA and Cancer Risk for Patients With Primary Biliary Cholangitis

Full Article URL: <a target="_blank" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842991">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842991
Textarea URL (this page): <a href="https://textarea.nl/i/eNrLKCkpKLbS189KzE3MSy0pzy_K1kvOz9XPyi8tykvMKUaWyC9IzdNPK83JSSwqyUzOSdU3sjAxsrQ0BACOMRll_2025-12-19">https://textarea.nl/i/eNrLKCkpKLbS189KzE3MSy0pzy_K1kvOz9XPyi8tykvMKUaWyC9IzdNPK83JSSwqyUzOSdU3sjAxsrQ0BACOMRll_2025-12-19
Source: https://jamanetwork.com/rss/site_214/187.xml
Jamanetwork.com Open: https://jamanetwork.com/journals/jamanetworkopen
Publication date: 2025-12-19 00:00:00
Last retrieval: 2025-12-20 06:45:29.897140

00:00 - 19 Dec 2025

This cohort study uses electronic health record data to compare cancer incidence among adults with primary biliary cholangitis who were or were not treated with ursodeoxycholic acid (UDCA).